Projects

  • Snakebite Treatment and Prevention
  • Access to Insulin
  • Medicines in Europe
  • Prices, Availability & Affordability
  • Artificial Intelligence and Medicines
  • Sexual and Reproductive Health
  • Supporting Healthy Adolescents
  • Resources
  • Publications
  • Politics Of Medicines Encyclopaedia
  • COVID-19 Response
  • Partners for Change
  • En français: Santé sexuelle et reproductive
  • Soutenir la santé des adolescents
  • AI and Health Inequalities in the EU

Work With Us

  • Partners
  • Access to Medicine Movement
  • Jobs
  • Media
  • News
  • Media Resource
  • Blog Posts
  • Events

About

  • Mission, vision, core principles & impact
  • Financial info, statutes, policies & governance
  • Team
  • Testimonials
  • Contact us

Support our projects

Donate

Join the Movement

AAA
Health Action International
  • Publications
  • News

Donate

Projects

  • Snakebite Treatment and Prevention
  • Access to Insulin
  • Medicines in Europe
  • Prices, Availability & Affordability
  • Artificial Intelligence and Medicines
  • Sexual and Reproductive Health
  • Supporting Healthy Adolescents
  • Resources
  • Publications
  • Politics Of Medicines Encyclopaedia
  • COVID-19 Response
  • Partners for Change
  • En français: Santé sexuelle et reproductive
  • Soutenir la santé des adolescents
  • AI and Health Inequalities in the EU

Work With Us

  • Partners
  • Access to Medicine Movement
  • Jobs
  • Media
  • News
  • Media Resource
  • Blog Posts
  • Events

About

  • Mission, vision, core principles & impact
  • Financial info, statutes, policies & governance
  • Team
  • Testimonials
  • Contact us

Support our projects

Donate

Join the Movement

Corporate funding linked to EU patient & consumer groups policy

Home > News > Corporate funding linked to EU patient & consumer groups policy

Share via:

  • Facebook
  • Twitter
  • LinkedIn
  • More

HAI Europe’s latest research has established a link between patient and consumer groups’ perspectives on EU medicines policies and the funding they receive from the pharmaceutical industry.


Please see our Press Release, as well as the two-page Factsheet and complete Research Article (links to website)

Tags
  • Civil Society
  • Conflicts of Interest
  • Medicines in Europe
Print or PDF
Print this page
Download this page

Related News

  • HAI Europe survey reveals new data on financial transparency of patient and consumer organisations
  • EU lobby transparency book launch by ALTER-EU
  • EU Global Health Communication
  • Patient Groups need dose of transparency
  • Patient advocacy groups: another tool to boost compliance?
  • Medicines manufacturers have clear motives for financing the patient voice
  • Public Event on EU-MERCOSUR in Buenos Aires
  • EU Global Health Council Conclusions presented at WHA
  • Finnish study: Drug companies see added value of patient group sponsorship
  • EU Policy Opportunities in Biomedical Innovation and the Public Good
Join the movement

Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere

Donate Become a Member

Projects
  • Snakebite Treatment and Prevention
  • Access to Insulin
  • Sexual and Reproductive Health
  • Medicines in Europe
  • Prices, Availability & Affordability
  • Artificial Intelligence and Medicines
  • Supporting Healthy Adolescents
About Us
  • Vision, Mission & Impact
  • History
  • Governance
Work With Us
  • Donate
  • Partner with us
  • Jobs & Internships
Contact Us

Health Action International
Overtoom 60 (2)
1054 HK Amsterdam

The Netherlands

+31 (0) 20 412 4523
info@haiweb.org

© 2023 Health Action International
  •  
website creatie yourstyle
Share via
Facebook
Twitter
LinkedIn
Mix
Email
Print
Copy Link
Powered by Social Snap
Copy link
CopyCopied
Powered by Social Snap
This website uses cookies to personalize the content and marketing of our website, to provide additional features and to analyze website traffic.Accept